CVS Health vs. UnitedHealth: Comparing Revenue Trends for These Healthcare Companies

Source Motley_fool

Key Points

  • UnitedHealth generates higher overall revenue, though CVS Health has occasionally narrowed the gap between the two companies.

  • Both companies experienced steady quarter-over-quarter revenue expansion through late 2025 before posting slight sequential declines in early 2026.

  • Investors should watch whether these recent revenue contractions represent temporary fluctuations or the beginning of a longer stabilization trend for both companies.

  • 10 stocks we like better than CVS Health ›

CVS Health: Managing Services and Revenue Shifts

CVS Health (NYSE:CVS) primarily generates revenue by offering health insurance, managing pharmacy benefit programs, and operating retail pharmacies across the country.

It received court approval to sell its Omnicare business to GenieRx, while it reported an approximately 3% net income margin for the quarter ended March 31, 2026.

UnitedHealth: Steady Scale and Operational Adjustments

UnitedHealth (NYSE:UNH) provides health benefit plans for employers and individuals while delivering direct medical care and pharmacy management services.

It announced a phased reduction of prior authorization requirements for rural providers, and it generated an approximately 6% net income margin for the quarter ended March 31, 2026.

Why Revenue Matters for Retail Investors

Revenue serves as a straightforward measure of total sales volume before any expenses are deducted. This metric helps investors measure a company’s overall size, market footprint, and long-term trajectory.

Cvs Health vs UnitedHealth Revenue chart

Quarterly Revenue for CVS Health and UnitedHealth

Quarter (Period End)CVS Health RevenueUnitedHealth Revenue
Q2 2024 (June 2024)$91.2 billion$98.9 billion
Q3 2024 (Sept. 2024)$95.4 billion$100.8 billion
Q4 2024 (Dec. 2024)$97.7 billion$100.8 billion
Q1 2025 (March 2025)$94.6 billion$109.6 billion
Q2 2025 (June 2025)$98.9 billion$111.6 billion
Q3 2025 (Sept. 2025)$102.9 billion$113.2 billion
Q4 2025 (Dec. 2025)$105.7 billion$113.2 billion
Q1 2026 (March 2026)$100.4 billion$111.7 billion

Data source: Company filings. Data as of June 23, 2026.

Foolish Take

In comparing the revenue trends for CVS and UnitedHealth, it’s important to note that, while they operate in the healthcare sector, their business models are different. CVS relies substantially on retail sales through its 9,000 pharmacy locations. This segment produced $32 billion of the company’s $100.4 billion in first-quarter revenue. As is common for the retail sector, CVS sees its largest sales in the fourth quarter.

UnitedHealth concentrates on its health system comprised of clinics and health insurance coverage. It is exiting its non-U.S. businesses to focus on its core operations. Its year-over-year revenue growth is not as strong as CVS. In Q1, UnitedHealth’s $111.7 billion was a 2% increase over 2025.

CVS boasts the more robust sales growth. Its Q1 revenue represented a 6% year-over-year jump. It raised its full-year guidance, and UnitedHealth did as well, indicating both are anticipating a strong year ahead, and making them promising investments in the healthcare industry.

Should you buy stock in CVS Health right now?

Before you buy stock in CVS Health, consider this:

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and CVS Health wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.

Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $418,761!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,195,804!*

Now, it’s worth noting Stock Advisor’s total average return is 918% — a market-crushing outperformance compared to 208% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.

See the 10 stocks »

*Stock Advisor returns as of July 5, 2026.

Robert Izquierdo has positions in CVS Health and UnitedHealth Group. The Motley Fool recommends CVS Health and UnitedHealth Group. The Motley Fool has a disclosure policy.

Disclaimer: For information purposes only. Past performance is not indicative of future results.
placeholder
Anthropic releases Claude Fable 5AI giant Anthropic has on Monday released Claude Fable 5, a general-access version of its Mythos-class AI, which the company claims outperforms every model it has previously made publicly available. In addition, a restricted variant of the Mythos AI called Claude Mythos 5 will ship to US government cyber defenders through the existing Project Glasswing...
Author  Cryptopolitan
Jun 10, Wed
AI giant Anthropic has on Monday released Claude Fable 5, a general-access version of its Mythos-class AI, which the company claims outperforms every model it has previously made publicly available. In addition, a restricted variant of the Mythos AI called Claude Mythos 5 will ship to US government cyber defenders through the existing Project Glasswing...
placeholder
XRP Price Prediction for July 2026: Can Buyers Finally Break the Downtrend?XRP (XRP) price trades near $1.05, caught between a year-long downtrend and a sudden burst of buying.July has historically rewarded XRP holders. This year the month arrives with on-chain accumulation
Author  Beincrypto
Jun 30, Tue
XRP (XRP) price trades near $1.05, caught between a year-long downtrend and a sudden burst of buying.July has historically rewarded XRP holders. This year the month arrives with on-chain accumulation
placeholder
What to Expect From Ethereum (ETH) in July 2026Ethereum (ETH) enters July 2026 trading near $1,570, close to multi-month lows, after recording its first run of three consecutive red quarterly candles in its history.On-chain data and price charts n
Author  Beincrypto
Jul 01, Wed
Ethereum (ETH) enters July 2026 trading near $1,570, close to multi-month lows, after recording its first run of three consecutive red quarterly candles in its history.On-chain data and price charts n
placeholder
What to Expect From Solana (SOL) in July 2026SOL trades near $77 after a 16% weekly bounce, yet it remains about 74% below its record high. On-chain activity is climbing toward yearly highs as the price attempts to bottom.The contrast sets up a
Author  Beincrypto
Jul 02, Thu
SOL trades near $77 after a 16% weekly bounce, yet it remains about 74% below its record high. On-chain activity is climbing toward yearly highs as the price attempts to bottom.The contrast sets up a
placeholder
Elon Musk Sends SpaceX Shares Lower With Two-Word AI Device DenialElon Musk dismissed a Wall Street Journal report that SpaceX built a prototype AI device, calling it “utterly false”. SpaceX stock (SPCX) fell about 7% on Wednesday as investors weighed the conflictin
Author  Beincrypto
Jul 02, Thu
Elon Musk dismissed a Wall Street Journal report that SpaceX built a prototype AI device, calling it “utterly false”. SpaceX stock (SPCX) fell about 7% on Wednesday as investors weighed the conflictin
goTop
quote